~~<i id='7EA1F9D749'><strike id='7EA1F9D749'><tt id='7EA1F9D749'><pre id='7EA1F9D749'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

knowledge

explore

author：leisure time 2025-09-27 12:56:10 - browse：5

Neumora, a neuroscience startup founded by VC Arch Venture Partners, hopes to become one of the few biotechs to go public this year.

The company filed paperwork for an IPO with the Securities and Exchange Commission on Friday. It did not state how many shares it plans to sell or at what price.

The biotech had begun planning for an IPO last year, STAT reported in June 2022. It raised $112 million in what would turn out to be a crossover round last October.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： Update the Apgar Score to remove skin color

hotspot

focus

hotspot

leisure time

hotspot

explore

AdobeThechanginglandscapeofdrugpricingpolicyintheU.S.hasimplicationsfortheglobalpaceanddirectionofin

WSS

Ripples from Flovent's discontinuation is killing children with asthma

To spot an incipient stroke, tiny brain probe acts ‘like a microscope’

The White House hikes tariffs on plastic syringes made in China

TikTok, Instagram influencers need more rules for drug ads

Microsoft launches AI tool for clinical documentation through Epic

Readout Newsletter: Biogen, Ionis, Johnson & Johnson news

knowledge

explore

hotspot

The cancer drug shortage isn’t new — and neither are the solutions

The White House hikes tariffs on plastic syringes made in China

At least 13 dead in Texas as scorching temps continue

FDA sets aggressive timeline for overhauling inspection procedures

Activists slam private health insurers over coverage restrictions

What a koala virus tells us about the human genome

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Readout Newsletter: Parkinson's study, Gilead, CG Oncology

The high cost of giving birth even with insurance

HHS suspends federal funding for EcoHealth Alliance

focus

Lilly’s weekly insulin works as well as daily products, new studies show

WuXi Biologics execs register to lobby as Congress comes for the company

Dana Farber says 6 studies to be retracted and 31 corrected

Obesity drug from Roche shows promise in early study

HPV vaccine, cervical cancer study delivers historic results

Maisha Meds is a PBM, but don't call it that

hotspot

leisure time

hotspot

explore